Major key industry players operating in the global atrial fibrillation market are Johnson & Johnson, Pfizer, Sanofi S.A, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Company, Limited and AstraZeneca.
Selbyville, United States - May 22, 2019 /MarketersMedia/ —
>> Increasing rate of geriatric population across the world is one of the major growth augmenting factors, since people above the age of 65 years are more prone to chronic diseases such as atrial fibrillation, diabetes, hypertension, etc.
>> Rising prevalence of cardiovascular diseases, especially in the U.S. will further boost the growth of atrial fibrillation drugs market in the forthcoming years.
>> Recent advancements in atrial fibrillation drugs driven by various innovations in the market will enhance the market growth.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/3253
The U.S. atrial fibrillation drugs market is the largest in the world and projected to expand at a CAGR of 2.4% over the forecast period. During the forecast timeframe, it will continue to grow with stable growth and lead the industry at a global level. Increasing geriatric population, rising venture capital investments by manufacturing firms, growing adoption rate of new pharmaceutical drugs to address severe conditions of patients suffering from atrial fibrillation in the country should drive the U.S. atrial fibrillation drugs market during the projection years.
Global Atrial Fibrillation Drugs Market will surpass USD 17,000 million by 2025; according to a new research study published by Global Market Insights, Inc.
Anticoagulants segment of atrial fibrillation drugs market was valued at around USD 11,554.6 million in the year 2018. Anticoagulants were introduced with an aim to reduce the rate of stroke in individuals suffering from atrial fibrillation. Patients with atrial fibrillation should be considered for antiplatelet or anticoagulation therapy based on patient's age and presence of other risk factors. A significant rise in the incidence of atrial fibrillation associated strokes over the recent years have increased the demand of anticoagulants thus, augmenting atrial fibrillation market growth.
Use of atrial fibrillation drugs for paroxysmal condition will grow at 2.9% over the estimation period. The paroxysmal atrial fibrillation occurs when there are irregular electric pathways in the heart and the heart is not pumping enough oxygen-rich blood, that leads to erratic heart rates that can last for upto 24 hours. The occurrence of paroxysmal atrial fibrillation is evidently increasing among the geriatric population as well as in young generation owing to rise in factors such as valvular disfunctions, coronary artery disease, previous heart surgery etc. Hence, the above mentioned reasons will augment the growth of atrial fibrillation drugs market.
Application of atrial fibrillation drugs market in heart rhythm control was valued at USD 3,312.4 million in the year 2018. Heart rhythm control is the maintenance and acute restoration of sinus rhythm in patients suffering from atrial fibrillation. The achievement of heart rhythm control can indeed reduce atrial fibrillation-associated mortality and morbidity. Patients that have coexistent cardiovascular diseases such as obstructive sleep apnea, hypertension, valvular heart disease and heart failure have a much higher increased risk for progression of arrhythmia. Hence, the increasing incidence of such cardiovascular diseases coupled with geriatric population will augment heart rhythm control segment growth.
Oral atrial fibrillation drug administration market will grow at 3.1% over the forecast period. The aim of medical therapy for patients suffering from atrial fibrillation are to avoid the risk of complications, sustain sinus rhythm and minimize atrial fibrillation symptoms. Oral drug therapies such as warfarin denotes the cornerstone of anticoagulant oral therapy for patients at high risk of thromboembolic events. With increase in incidence of atrial strokes across the world, oral drug therapies are experiencing an upward trajectory of atrial fibrillation dugs market growth.
The use of atrial fibrillation drugs in hospitals is estimated to grow at 3% over the forecast period. Rising popularity of anticoagulant and antiarrhythmic drugs in developed and developing countries will strongly contribute to larger demand for atrial fibrillation drugs in hospitals. Moreover, increasing investments and partnerships with various manufacturing firms will further augment the atrial fibrillation drugs market growth.
Side effects associated with the regular intake of atrial fibrillation drugs is one of the major growth impending factors. Side effects such as excessive bleeding, tiredness, etc. will hamper market growth. Moreover, lack of awareness among people about the latest pharmaceutical therapies is another growth hindering factor.
Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/3253
Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Global Market Insights, Inc.
Website: https://www.gminsights.com/pressrelease/atrial-fibrillation-drugs-market
Source URL: https://marketersmedia.com/factors-behind-17000-million-atrial-fibrillation-drugs-market/515582
Source: MarketersMedia
Release ID: 515582
